Analyst’s outlook: CorMedix, Inc. (CRMD)

CorMedix, Inc. (CRMD) stock price moved 0.40% away from 20-Days Simple Moving Average, 9.42% from 50-Days Simple Moving Average and separated 108.39% from 200 Days Simple Moving Average. CorMedix, Inc. (CRMD) reported no change 0.00% in recent buying and selling session with closing price of $ 1.39. The stock’s traded 0.65 million shares in session while it holds an average volume of 3.47 million shares. The CRMD switched 707.67% away from its 52 week minimum and distanced -42.08% from its 52 week peak. The volatility change in the previous week has observed by 6.98% and experienced of 12.24% change in the last month.

The short ratio in the company’s stock is documented at 3.84 and the short float is around of 14.19%. Beta factor, which measures the riskiness of the security, was registered at 1.98. The Company kept a record of 93.83 million floated shares and 93.83 million shares outstanding. The average true range of the stock is observed at 0.15 and the relative strength index of the stock is recorded at 54.50.

Consensus Recommendation:

Analyst notified mean rating at 2.00 after consensus analysis. (Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Keep in mind that Investors should not rely only on an analyst’s recommendation when taking a decision whether to buy, hold, or sell a stock. Instead, they should also do their own research—such as reading the prospectus for new companies or for public companies, the quarterly and annual reports filed with the SEC—to confirm whether a particular investment is appropriate for them in light of their individual financial circumstances.

CorMedix, Inc. (CRMD) Stock Profitability Levels:

Gross profit margin is 37.20%. The larger the gross profit margin, the better for the company. Return on assets ratio of the Company was -424.30%.

For the past 5 years, The Company’s EPS growth has been nearly -15.10%. Analyst established EPS growth expected to grow of 7.80% for this year and EPS growth for next year is likely to attain at 35.70%.

Looking about the past performance history, the company jumped 5.30% for the last five trades and expanded 5.30% in one month period. The stock augmented 15.83% during the past three month period and escalated 460.94% in half year. During the yearly overview it upgraded 162.26% and shown 7.75% year to date performance.

Jose Gable

Jose Gable

Jose has a wide look on current Healthcare and biotech news and events. Jose has done its MBA in 1999 from U.S. National University. At our place, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Jose personal interests in health, fitness, animal care, gardening, travel, world politics, and current social issues, but always willing to learn something new. The more shareholders that are interested in the stock for reasons based on their respective investment mandates and the more likely it will move higher. Address: 3332 Farm Meadow Drive, Nashville, TN 37214 Phone: +1 931-236-3269 Email: Jose@talktraders.com